IGC Announces Results of its 2022 Annual Stockholders Meeting
12 Septembre 2022 - 1:00PM
Business Wire
India Globalization Capital, Inc. (“IGC” or the “Company”) (NYSE
American: IGC) announces that during its Annual Meeting of
Stockholders scheduled for and convened on September 9, 2022 (the
“Annual Meeting”), all proposals as disclosed on the Definitive
Proxy Statement on Schedule 14A filed with the SEC on July 25,
2022, were passed by the requisite vote of the stockholders. Only
stockholders of record on the record date of July 13, 2022 were
entitled to and requested to vote at the Annual Meeting.
At the Annual Meeting, the following proposals were approved by
the requisite vote of the stockholders: (i) the proposal to elect
Mr. Ram Mukunda and Congressman James Moran to the Company’s Board
of Directors to serve as Class C directors until the 2025 annual
meeting of stockholders and to elect Ms. Claudia Grimaldi to the
Company’s Board of Directors to serve as a Class A director until
the 2023 annual meeting of stockholders; (ii) the proposal to
ratify Manohar Chowdhry & Associates, as the Company’s
independent registered public accounting firm for the 2023 fiscal
year; and (iii) the grant of 3,000,000 shares of common stock to be
granted from time to time to the Company’s current and new
employees, advisors, directors, and consultants by the Company
Board of Directors, pursuant to certain metrics including
performance, vesting, and incentive as set by the Company’s Board
of Directors and or the CEO.
About IGC:
IGC has two segments: Life Sciences and Infrastructure. The
company is based in Maryland, U.S.A.
Forward-looking Statements: This press release contains
forward-looking statements. These forward-looking statements are
based largely on IGC’s expectations and are subject to several
risks and uncertainties, certain of which are beyond IGC’s control.
Actual results could differ materially from these forward-looking
statements as a result of, among other factors, the Company’s
failure or inability to commercialize one or more of the Company’s
products or technologies, including the products or formulations
described in this release, or failure to obtain regulatory approval
for the products or formulations, where required; general economic
conditions that are less favorable than expected, including as a
result of the ongoing COVID-19 pandemic; the FDA’s general position
regarding cannabis- and hemp-based products; and other factors,
many of which are discussed in IGC’s SEC filings. IGC incorporates
by reference the human trial disclosures and Risk Factors
identified in its Annual Report on Form 10-K filed with the SEC on
June 23, 2022, as if fully incorporated and restated herein. In
light of these risks and uncertainties, there can be no assurance
that the forward-looking information contained in this release will
occur.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220912005387/en/
Claudia Grimaldi 301-983-0998
IGC Pharma (AMEX:IGC)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
IGC Pharma (AMEX:IGC)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024